Emma L. Herbach

Emma L. Herbach

Auto-generated profile, based on publicly available information

Emma L. Herbach

Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
EHEmma Herbach
Emma Herbach
MOMichael Anthony O'Rorke
Michael Anthony O'Rorke
RCRyan M. Carnahan
Ryan M. Carnahan
BMBradley D. McDowell
Bradley D. McDowell
BABryan Allen
Bryan Allen
ECElizabeth Chrischilles
Elizabeth Chrischilles
Background: We compared cardiac outcomes for surgery‐eligible patients with stage III non‐small‐cell lung cancer treated adjuvantly or neoadjuvantly with chemotherapy versus chemo‐radiation therapy in the Surveillance, Epidemiology and End Results‐Medicare database. Methods and Results: Patients were age 66+, had stage IIIA/B resectable non‐small‐cell lung cancer diagnosed between 2007 and 2015, and received adjuvant or neoadjuvant chemotherapy or chemo‐radiation within 121 days of diagnosis. Patients having chemo‐radiation and chemotherapy only were propensity‐score matched and followed from day 121 to first cardiac outcome, noncardiac death, radiation initiation by patients who received chemotherapy only, fee‐for‐service enrollment interruption, or December 31, 2016. Cause‐specific hazard ratios (HRs) and competing risks subdistribution HRs were estimated. The primary outcome was the first of these severe cardiac events: acute myocardial infarction, other hospitalized ischemic heart disease, hospitalized heart failure, percutaneous coronary intervention/coronary artery bypass graft, cardiac death, or urgent/inpatient care for pericardial disease, conduction abnormality, valve disorder, or ischemic heart disease. With median follow‐up of 13 months, 70 of 682 patients who received chemo‐radiation (10.26%) and 43 of 682 matched patients who received chemotherapy only (6.30%) developed a severe cardiac event ( P =0.008) with median time to first event 5.45 months. Chemo‐radiation increased the rate of severe cardiac events (cause‐specific HR: 1.62 [95% CI, 1.11–2.37] and subdistribution HR: 1.41 [95% CI, 0.97–2.04]). Cancer severity appeared greater among patients who received chemo‐radiation (noncardiac death cause‐specific HR, 2.53 [95% CI, 1.93–3.33] and subdistribution HR, 2.52 [95% CI, 1.90–3.33]). Conclusions: Adding radiation therapy to chemotherapy is associated with an increased risk of severe cardiac events among patients with resectable stage III non‐small‐cell lung cancer for whom survival benefit of radiation therapy is unclear.

1 February 2021 in Annals of Epidemiology
Verified
Journal Article
Closed access
EHEmma L. Herbach
Emma L. Herbach
KWKristin S. Weeks
Kristin S. Weeks
MOMichael O'ROrke
Michael O'ROrke
NNNicole Novak
Nicole Novak
MSMarin L. Schweizer
Marin L. Schweizer

12 July 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
EHEmma L. Herbach
Emma L. Herbach
SNSarah H Nash
Sarah H Nash
ILIngrid M. Lizarraga
Ingrid M. Lizarraga
RCRyan M. Carnahan
Ryan M. Carnahan
KWKai Wang
Kai Wang
MCMary E. Charlton
Mary E. Charlton
Background: Racial and ethnic disparities in guideline-recommended breast cancer treatment are well documented, however studies including diagnostic and staging procedures necessary to determine treatment indications are lacking. The purpose of this study was to characterize patterns in delivery of evidence-based services for the diagnosis, clinical workup, and first-line treatment of breast cancer by race–ethnicity. Methods: SEER-Medicare data were used to identify women diagnosed with invasive breast cancer between 2000 and 2017 at age 66 or older (n = 2,15,605). Evidence-based services included diagnostic procedures (diagnostic mammography and breast biopsy), clinical workup (stage and grade determination, lymph node biopsy, and HR and HER2 status determination), and treatment initiation (surgery, radiation, chemotherapy, hormone therapy, and HER2-targeted therapy). Poisson regression was used to estimate rate ratios (RR) and 95% confidence intervals (CI) for each service. Results: Black and American Indian/Alaska Native (AIAN) women had significantly lower rates of evidence-based care across the continuum from diagnostics through first-line treatment compared to non-Hispanic White (NHW) women. AIAN women had the lowest rates of HER2-targeted therapy and hormone therapy initiation. While Black women also had lower initiation of HER2-targeted therapy than NHW, differences in hormone therapy were not observed. Conclusions: Our findings suggest patterns along the continuum of care from diagnostic procedures to treatment initiation may differ across race–ethnicity groups. Impact: Efforts to improve delivery of guideline-concordant treatment and mitigate racial–ethnic disparities in healthcare and survival should include procedures performed as part of the diagnosis, clinical workup, and staging processes.

28 March 2024 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
EHEmma L. Herbach
Emma L. Herbach
MCMichaela Curran
Michaela Curran
MRMya L. Roberson
Mya L. Roberson
RCRyan M. Carnahan
Ryan M. Carnahan
BMBradley D. McDowell
Bradley D. McDowell
MCMary Charlton
Mary Charlton

1 April 2022 in Annals of Epidemiology
Verified
Journal Article
Closed access
TGTamala Gondwe
Tamala Gondwe
EHEmma Herbach
Emma Herbach
MCMatthew Cvitanovich
Matthew Cvitanovich
JBJoel Begay
Joel Begay
ESEndia Santee
Endia Santee
BHBertha Hidalgo
Bertha Hidalgo

5 September 2024 in Preventive Oncology & Epidemiology
Verified
Journal Article
Open access
EHE. Herbach
E. Herbach
CBC. Brown
C. Brown
BMB. Mahal
B. Mahal
ALA. Leavitt
A. Leavitt
ARA. Rivera
A. Rivera
EKE. Kobetz
E. Kobetz